NCT04806243Unknown2 期
A Phase II, Second-line, Single-arm Clinical Trial of Carelizumab Combined With Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 69
- 试验地点
- 1
- 主要终点
- os（overall survival）
研究概览
简要总结
To investigate the efficacy and safety of carelizumab combined with regorafenib in second-line treatment for patients with primary hepatocellular carcinoma.
详细描述
Currently, there is little experience in the application of targeted drugs combined with immunotherapy. Through this study, we hope to explore the optimal population for the use of carelizumab combined with regorafenib in the second-line treatment of hepatocellular carcinoma (HCC), as well as the efficacy and safety.
This research is a single-center trials phase II second-line, single arm, explore the clinical outcome of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Not convenient to disclose
排除标准
- •Not convenient to disclose
研究组 & 干预措施
Carelizumab Combined With Regorafenib arm
Experimental
干预措施: Regorafenib Pill&Camrelizumab (Drug)
结局指标
主要结局
os（overall survival）
时间窗: 21 days
overall survival
次要结局
- ORR（Overall Response Rate）(21 days)
- DCR（disease control rate）(21 days)
- DoR(21 days)
- PFS（progression-free survival）(21 days)
- TTP（Time-To-Progression）(21 days)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCCHead and Neck Squamous Cell CarcinomaNCT04399785Xingchen Peng34
尚未招募
2 期
Second Line Therapy for Advanced Intrahepatic CholangiocarcinomaIntrahepatic CholangiocarcinomaNCT05535647Tianjin Medical University Cancer Institute and Hospital60
进行中（未招募）
2 期
Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC PatientsSquamous Cell Carcinoma of Head and NeckNCT05673577Fudan University40
终止
2 期
Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus BevacizumabMetastatic DiseaseColorectal NeoplasmsNCT02175654Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)15
招募中
2 期
A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILsBreast CancerTriple-Negative Breast CancerNCT05556200Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University58